There’s been an enormous leadership change at Hydrafacial owner BeautyHealth.

Andrew Stanleick will depart the corporate as president and chief executive officer and relinquish his board seat, effective Sunday. Marla Beck, an organization board director and Bluemercury founder, will step in as interim CEO while the corporate completes a proper seek for a everlasting successor. She founded the sweetness retailer in 1999, selling it to Macy’s in 2015.

“It has been an honor to steer BeautyHealth, and I would really like to thank Brent [Saunders] and the board for the chance,” said Stanleick, who will serve in an advisory role with the corporate through the tip of the 12 months. “I leave inspired by the fervour of our teams, providers and consumers and the brand-forward vision that Hydrafacial has set out. I think deeply in the long run opportunity of the skilled beauty and aesthetics sector — and I remain an ardent supporter of BeautyHealth.”

Stanleick joined BeautyHealth in January 2022. Prior to that, he served as executive vice chairman, Americas, of Coty Inc. and global CEO of Coty’s three way partnership with Kylie Jenner’s Kylie Cosmetics and Kim Kardashian West’s KKW Beauty brand.

During his tenure at BeautyHealth, he forged partnerships with the likes of Dior, Dr. Dennis Gross and Jennifer Lopez, increased Hydrafacial’s presence across the globe and oversaw the corporate reaching profitability.

But in its third-quarter results, released Monday, BeautyHealth said while net revenue was up 10 percent year-over-year, on the strength of performance in Asia-Pacific, the quarter was overshadowed by lower-than-expected U.S. revenue and $63.1 million in restructuring charges related to device upgrades of early generation Syndeo Hydrafacial devices.

In consequence, the corporate is revising its fiscal 12 months 2023 net sales guidance to a spread of $385 million to $400 million, its fiscal-year-adjusted earnings before interest, taxes, depreciation and amortization margin guidance to a spread of 5 to six percent and is suspending its long-term 2025 financial outlook.

“We’re focused on protecting Hydrafacial’s strong brand equity as we address the Syndeo provider experience challenges,” said BeautyHealth chief financial officer Michael Monahan. “We’re confident that, with our strategy, we’ll return Hydrafacial to the reliable standard that our customers have come to expect from us and keep their trust — and, with this, reaccelerate Syndeo adoption within the U.S.”

The corporate plans to only market and sell Syndeo 3.0 devices attributable to provider experience issues with earlier generation Syndeo devices. It has designated all Syndeo 1.0 and a pair of.0 devices on-hand as obsolete, leading to a listing write-down in cost of sales of $18.8 million through the three months ended Sept. 30.

The corporate incurred costs of $12.3 million related to the Syndeo Program and has accrued a further $32.1 million for the estimated cost to remediate or upgrade or exchange the remaining Syndeo 1.0 and a pair of.0 devices.

BeautyHealth’s share price closed up 8.3 percent to $3.90. In after-hours trading when the leadership changes and quarterly results were released, the share price fell about 38 percent.